EGFR and non-small cell lung carcinoma: Subsequent studies in EGFR mutated non‐small cell lung cancer confirmed that FASN-associated fatty acid metabolic pathway upregulation was the main principal for tyrosine kinase inhibitor (TKI)‐resistant EGFR mutated NSCLC growth (47).